Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Profit before tax (PBT) stood at Rs 1,835 crore in Q2 FY26, down 4.26% year on year.
EBITDA for the quarter stood at Rs 2,351 crore, up 3% as against Rs 2 ,280 crore posted in Q2 FY25.
In its global generics business, North America contributed Rs 3,240.8 crore in revenue, a 13.07% year-on-year decline. Revenue from Europe surged 138.50% to Rs 1,376.2 crore, The India business generated revenue of Rs 1,578 crore, registering an 12.94% YoY.
Revenue from pharmaceutical services and active ingredients (PSAI) came in at Rs 944.99 crore, a 12.40% YoY increase.
In Q2 FY26, the company advanced its global presence through key acquisitions, product launches, and partnerships. It acquired the STUGERON portfolio across 18 APAC and EMEA markets for $50.5 million and launched Colozo (Linaclotide) and PCAB (Tegoprazan) in India.
Globally, it partnered with Unitaid, CHAI, and Wits RHI to make Lenacapavir affordable in 120 countries. Regulatory approvals were secured for Semaglutide in India, the denosumab biosimilar in Europe, and COVA 302 for ALS.
The company integrated two-thirds of its NRT business and launched Sacubitril Valsartan and fluorouracil cream in the US, as well as Skorolox in Russia, underscoring its focus on portfolio expansion and global market growth.
On a half year basis, the company’s consolidated net profit rose 7.84% to Rs 2,854.9 crore on 10.58% jump in revenue from operations to Rs 17,350.3 crore in H1 FY26 over H1 FY25.
Commenting on the results, Co-Chairman & MD, G V Prasad said: 'Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRTJ portfolio, which helped offset the decline in U.S. Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and Pursuing business development initiatives.'
Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
Shares of Dr Reddys Laboratories rose 0.32% to close at Rs 1,284 on Friday, 24 October 2025.
Dr Reddys Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 1280.7, up 1.97% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 25868.3. The Sensex is at 84466.7, up 0.61%. Dr Reddys Laboratories Ltd has dropped around 1.59% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has dropped around 0.17% in last one month and is currently quoting at 22253.75, up 0.68% on the day. The volume in the stock stood at 8.63 lakh shares today, compared to the daily average of 19.74 lakh shares in last one month.
The benchmark October futures contract for the stock is quoting at Rs 1280.5, up 1.68% on the day. Dr Reddys Laboratories Ltd is down 4.39% in last one year as compared to a 4.39% gain in NIFTY and a 3.11% gain in the Nifty Pharma index.
The PE of the stock is 15.21 based on TTM earnings ending June 25.
Dr Reddys Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 1233.4, down 0.1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24664.4. The Sensex is at 80439.96, up 0.09%.Dr Reddys Laboratories Ltd has eased around 3.63% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has eased around 1.41% in last one month and is currently quoting at 21475.3, down 0.01% on the day. The volume in the stock stood at 14.52 lakh shares today, compared to the daily average of 13.62 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1226.1, down 1.06% on the day. Dr Reddys Laboratories Ltd tumbled 8.62% in last one year as compared to a 4.39% slide in NIFTY and a 7.83% fall in the Nifty Pharma index.
The PE of the stock is 14.96 based on TTM earnings ending June 25.